WO2023240212 - GENETICALLY ENGINEERED CELLS HAVING ANTI-CD133 / ANTI-EGFR CHIMERIC ANTIGEN RECEPTORS, AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2023/240212
Publication Date
14.12.2023
International Application No.
PCT/US2023/068159
International Filing Date
08.06.2023
Title **
[English]
GENETICALLY ENGINEERED CELLS HAVING ANTI-CD133 / ANTI-EGFR CHIMERIC ANTIGEN RECEPTORS, AND USES THEREOF
[French]
CELLULES GÉNÉTIQUEMENT MODIFIÉES AYANT DES RÉCEPTEURS ANTIGÉNIQUES CHIMÉRIQUES ANTI-CD133/ANTI-CD22, ET LEURS UTILISATIONS
Applicants **
CENTURY THERAPEUTICS, INC.
Inventors
NASO, Michael, Francis
CARTON, Jill, Marinari
VORA, Parvez
BORGES, Luis
DOWER, Christopher
BLOEMBERG, Darin
Priority Data
63/350,380
08.06.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4348 | |
| EPO | Filing, Examination, Granting | 48560 | |
| Japan | Filing, Examination, Granting | 3728 | |
| South Korea | Filing, Examination, Granting | 5092 | |
| USA | Filing, Examination, Granting | 20790 |
Total:
82,518
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided are genetically engineered induced pluripotent stem cells (iPSCs) and derivative cells thereof expressing mono- and/or bi-specific chimeric antigen receptors (CAR) with anti-CD133 and anti-EGFR antigen binding domains, and methods of using the same. Also provided are compositions, polypeptides, vectors, and methods of manufacturing.[French]
L'invention concerne des cellules souches pluripotentes induites (iPSC) génétiquement modifiées et des cellules dérivées de celles-ci exprimant des récepteurs antigéniques chimériques (CAR) mono-et/ou bi-spécifiques avec des domaines de liaison à l'antigène anti-CD133 et anti-EGFR, et leurs méthodes d'utilisation. L'invention concerne également des compositions, des polypeptides, des vecteurs et des méthodes de fabrication.